Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston optimistic for coming years after strong 2004

This article was originally published in Clinica

Executive Summary

Boston Scientific has set itself ambitious sales and earnings targets for the coming three years, signalling its confidence that its drug-eluting stent (DES) franchise will be able to hold its ground in the face of increasing competition. The firm cornered 63% of the US DES market and 55% of the world market in the fourth quarter of 2004, in terms of dollar sales.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts